| ALABAMA |
Location: Birmingham
University of Alabama at Birmingham-
Division of Preventive Medicine
Trial Title and
Description:
Prevention of
Alzheimer's Disease by Vitamin E and Selenium
(PREADVISE)- The Prevention of Alzheimer's
disease by Vitamin E and Selenium (PREADVISE)
prevention trial is an important addition to the
Selenium and Vitamin E Cancer Prevention Trial
(SELECT). As a prevention trial, PREADVISE is trying
to find out if taking Selenium and/or Vitamin E
supplements can help to prevent memory loss and
dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Isabelle Joffrion
205-934-9502
ijoffrion@dopm.uab.edu
Back
to Top |
Location: University of Alabama at Birmingham
Trial Title and Description: Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
The purpose of this study is to test if bapineuzumab is effective and safe in treating Alzheimer’s Disease. In patients with Alzheimer’s, plaques are formed in the brain that are thought to be related to the progression of the disease. It is hoped that bapineuzumab will attach to the protein that forms the plaques and help the body remove it.
Enrollment Status: Actively recruiting
Study Dates: started recruiting November 2010 Expected Completion:
Condition: Alzheimer’s Disease
Age Eligibility: 50-88 years of age
Gender Eligibility: Both
Enrollment Goal: 1,000
Clinical Identifier: NCT00574132
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Pfizer
Contact Information:
Name: Sherer Thomson
Phone: 205-996-5987
Back to Top |
| ALASKA |
Location: Anchorage
Alaska
Regional Hospital
Trial Title and
Description:
Prevention of
Alzheimer's Disease by Vitamin E and Selenium
(PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Judith
Link
907-264-1579
judith.link@healthcare.com
Back
to Top |
Location: Anchorage
Providence Alaska Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by
Vitamin E and Selenium (PREADVISE) prevention trial is
an important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Kathleen
W. Shue
907-261-3109
kwilsack@provak.org
Back
to Top |
| ARIZONA |
Location: Phoenix
Banner Alzheimer’s Institute
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Sarah Medina-Rodriguez
602-839-4640
sarah.medina-rodriguez@bannerhealth.com
For more information, visit www.gapstudy.com
Back to Top |
Location: Phoenix
Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
Banner Alzheimer’s Institute
Lisa Cooper
602-239-6920
www.KiokuStudy.com
Back to Top |
Location: Phoenix
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Stephen
Flitman (for zip code 85013)
877-379-3718
Pierre Tariot (for zip code 85006- Not yet
recruiting)
602-239-6920
Jeffrey Gitt (for
zip code 85050)
602-288-4673
Back
to Top |
Location: Phoenix
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Stephen
Flitman
877-379-3718
Back
to Top |
Location: Sun City
Banner Sun Health Research Institute
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Elizabeth Karoll
623-974-7394
beth.karoll@bannerhealth.com
Back to Top |
Location: Sun City
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Maninder
Kahlon
877-379-3718
Back
to Top |
Location: Tucson
University of Arizona (Arizona Health Sciences Center)
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Susan Merski
520-626-4296
smerski@email.arizona.edu
For more information, visit www.gapstudy.com
Back to Top |
Location: Tucson
Trial Title and Description:
A Phase 2a Multi-center, randomized, double blind, placebo-controlled study to investigate the efficacy and safety of T-817MAa in patients with mild to moderate Alzheimer’s Disease.
Enrollment Status: Recruiting
Study Dates: Start November, 2007 Expected Completion: November, 2011
Condition: Alzheimer’s Disease
Age Eligibility: 50 – 90 years of age
Gender Eligibility: Male or Female
Enrollment Goal: 326
Clinical Identifier: NCT00663936
Study Phase: 2a
Study Type: Interventional
Sponsor: Toyama Chemical Co. Ltd
Contact Information:
Northwest NeuroSpecialists, PLLC
Dawn Brown
520-742-1833
www.KiokuStudy.com
Back to Top |
Location: Tucson
University of
Arizona
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Marjorie
Baldwin
520-626-4296
baldwinm@u.arizona.edu
Geoffrey Ahern
Back
to Top |
Location: Call for details
Trial Title and Description: A study of V950 in People with
Alzheimer's Disease-
The purpose of this study is to test the safety,
tolerability and immune response to an investigational
vaccine, V950.
Enrollment Status: Recruiting
Study Dates: Start: April 2007
Condition: Alzheimer's
disease
Age Eligibility: 55 and
above
Gender Eligibility: Both
Enrollment Goal: Call for
details
Clinical Identifier: NCT00464334
Study Phase: Phase
1
Study Type: Interventional
Sponsor: Merck
Contact Information:
Trial
Manager
888-577-8839
Back
to Top |
Location: Call for details
Trial Title and Description: Open-Label Extension Assessing Long
Term Safety of Rosiglitazone In Subjects with Mild To
Moderate Alzheimer's Disease-
This is an open-label extension to study 49653/461,
to assess the long-term safety of rosiglitazone
(extended release tablets) in subjects with mild to
moderate Alzheimer's disease.
Enrollment Status: Recruiting
Study Dates: Start: February
2006
Condition: Alzheimer's
disease
Age Eligibility: 50-85
Gender Eligibility: Both
Enrollment Goal: 60
Clinical Identifier: NCT00381238
Study Phase: Phase
2
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
877-379-3718
Back
to Top |
| ARKANSAS |
| CALIFORNIA |
Location: Chula
Vista
University of California, San Diego-Chula
Vista
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Clydene Nee
858-622-5747
Back
to Top |
Location: Fresno
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
David
Margolin (for zip code 93720)
Justine Kent (for
zip code 93720)
877-379-3718
Back
to Top |
Location: Glendale
Glendale
Memorial Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August
2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Mary
Eichenhofer
818-409-7653
Back
to Top |
Location: Irvine
University of California, Irvine – Alzheimer’s Disease Research Center
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Beatriz Yanez
949-824-3250
byanez@uci.edu
Back to Top |
Location: Irvine
University of
California, Irvine
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Catherine
McAdams-Ortiz
949-824-8726
cmcadams@uci.edu
Ruth Mulnard
Back
to Top |
Location: La Jolla
University of California, San Diego
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Elizabeth Ortega
858-677-1567
ejortega@ucsd.edu
For more information, visit www.gapstudy.com
Back to Top
|
Location: La Jolla
University
of California, San Diego
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Mary Pay
858-622-5804
mpay@ucsd.edu
Judith Rivera
858-622-5807
jrivera@ucsd.edu
David Weisman
Back
to Top |
Location: La
Jolla
University of California, San Diego
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by
Vitamin E and Selenium (PREADVISE) prevention trial is
an important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May
2002 Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National
Institute on Aging (NIA), National Cancer Institute
(NCI)
Contact Information:
Clydene Nee
858-622-5747
Back
to Top |
Location: La Mesa
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Jorge
Porras
877-379-3718
Back
to Top |
Location: Loma
Linda
VA Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Kimberly
A. Bluff
909-558-3107
bluffk@lom.med.va.gov
Back
to Top |
Location: Long Beach
CNS Network, Inc.
Trial Title and Description:
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients With Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease
The purpose of this Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due Alzheimer’s Disease (AD) or mild AD who test positive for amyloid plaque.
Enrollment Status: Recruiting
Study Dates: Start: March 2012 Expected Completion: February 2014
Condition: Alzheimer's disease
Age Eligibility: 55 years or older
Gender Eligibility: Male or Female
Enrollment Goal: 129
Clinical Identifier: NCT01561430
Study Phase: Phase 2
Study Type: Interventional
Sponsor: Eli Lilly and Company
Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com
Back to Top |
Location: Long Beach
CNS Network, Inc.
Trial Title and Description:
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (NOURISH AD)
This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.
Enrollment Status: Recruiting
Study Dates: Start: March 2013 Expected Completion: January 2015
Condition: Alzheimer's disease
Age Eligibility: 66-90
Gender Eligibility: Male or Female
Enrollment Goal: 480
Clinical Identifier: NCT01741194
Study Phase: Phase 2/3
Study Type: Interventional
Sponsor: Accera, Inc.
Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com
Back to Top |
Location: Long Beach
CNS Network, Inc.
Trial Title and Description:
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.
Enrollment Status: Recruiting
Study Dates: Start: November 2012 Expected Completion: July 2015
Condition: Alzheimer's disease
Age Eligibility: 18-89
Gender Eligibility: Male or Female
Enrollment Goal: 500
Clinical Identifier: NCT01689233
Study Phase: Phase 3
Study Type: Interventional
Sponsor: TauRx Therapeutics Ltd
Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com
Back to Top |
Location: Long Beach
CNS Network, Inc.
Trial Title and Description:
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3) (EPOCH)
The purpose of this study is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of Alzheimer's Disease (AD). The primary study hypotheses are that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) score and that at least one MK-8931 dose is superior to placebo at 78 weeks of treatment with respect to change from Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) score.
Enrollment Status: Recruiting
Study Dates: Start: November 2012 Expected Completion: January 2017
Condition: Alzheimer's disease
Age Eligibility: 55-85
Gender Eligibility: Male or Female
Enrollment Goal: 1960
Clinical Identifier: NCT01739348
Study Phase: Phase 2/3
Study Type: Interventional
Sponsor: Merck
Contact Information:
Shelly Asbill
855-425-1515
shellyasbill@cnstrial.com
Back to Top |
Location: Long Beach
VAMC Long
Beach
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Francoise M.
Toussaint-Jones
562-826-5755
Back
to Top |
Location: Los Angeles
University of Southern California
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Mauricio Becerra
323-442-7534
mjbecerr@usc.edu
For more information, visit www.gapstudy.com
Back to Top |
Location: Los
Angeles
University of California, Los Angeles
Trial Title and Description: Anti-Oxidant Treatment of Alzheimer's
Disease-
The purpose of this study is to examine the safety
and effectiveness of two anti-oxidant treatment
regimens in patients with mild to moderate Alzheimer's
disease. The anti-oxidant treatments include vitamin E
+ C + alpha-lipoic acid, and Coenzyme Q
(CoQ).
Enrollment Status: Recruiting
Study Dates: Start: January
2006
Condition: Alzheimer's
disease
Age Eligibility: 60-85
Gender Eligibility: Both
Enrollment Goal: 75
Clinical Identifier: NCT00117403
Study Phase: Phase
1
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Jenny Bardens
310-794-6191
jbardens@mednet.ucla.edu
John Ringman
Back
to Top |
Location: Los
Angeles
University of California
Trial Title and Description: Depression in Alzheimer's Disease-
The purpose of this study is to learn whether
treating individuals with Alzheimer's disease and
depression with the anti-depressant medication
Sertraline (Zoloft) is helpful to people with
Alzheimer's disease and to their families and
caregivers.
Enrollment Status: Recruiting
Study Dates: Start: July 2004
Condition: Alzheimer's disease,
Depression
Age Eligibility: 18 and
above
Gender Eligibility: Both
Enrollment Goal: 130
Clinical Identifier: NCT00086138
Study Phase: Phase 2,
3
Study Type: Interventional
Sponsor: National Institute of
Mental Health (NIMH)
Contact Information:
Shirley Sian
323-442-7600
sian@usc.edu
Back
to Top |
Location: Los Angeles
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
David Trader
877-379-3718
Back
to Top |
Location: Newport Beach
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Philip
O'Carroll
877-379-3718
Back
to Top |
Location: Northridge
Northridge
Hospital Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Diane M. Killian
818-885-5458
Back
to Top |
Location: Oceanside
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Valentin Isacescu
877-379-3718
Back
to Top |
Location: Orange
University of California, Irvine – Brain Imaging Center
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Azita Adami
714-456-8517
aadami@uci.edu
Back to Top |
Location: Palo Alto
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Natalie
Rasgon
877-379-3718
Back
to Top |
Location: Rancho Mirage
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Richard Hubbard
760-773-9117
Back
to Top |
Location: Redondo Beach
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
George
Rederich
877-379-3718
Back
to Top |
Location: Reseda
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Robert Hutchman
877-379-3718
Back
to Top |
Location: Sacramento
GSK Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
William Au
877-379-3718
Back
to Top |
Location: San
Diego
GSK Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
John
Doria
877-379-3718
Back
to Top |
Location: San Francisco
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Jerome Goldstein
877-379-3718
Back
to Top |
Location: Santa Rosa
Santa Rosa
Memorial Hospital Regional CCOP
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Kris Haratigan
707-521-3820
Back
to Top |
Location: Sherman Oaks
GSK
Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Jose Schuster
877-379-3718
Back
to Top |
Location: Torrance
Harbor UCLA
Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Marie Jackson
310-222-5339
Back
to Top |
Location: Upland
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Arlene J.
Katchem
909-373-0381
Back
to Top |
Location: Call for details
Trial Title and Description: Enhancing Consent for Alzheimer's
Research (BWP-AD)-
The purpose of this study is to evaluate the
efficacy of an enhanced consent procedure for patients
with mild-to-moderate Alzheimer's disease, and to
identify factors and patient characteristics that
predict the degree to which enhanced consent is more
beneficial than routine consent
procedures.
Enrollment Status: Recruiting
Study Dates: Start: April 2006
Expected Completion: December 2011
Condition: Alzheimer's
disease
Age Eligibility: 50 and
above
Gender Eligibility: Both
Enrollment Goal: 272
Clinical Identifier: NCT00453544
Study Phase: N/A
Study Type: Interventional
Sponsor: National Institute on
Aging
Contact Information:
Tia
Thrasher
858-535-5795
tthrasher@ucsd.edu
Luz Pinto
858-642-3682
llpinto@ucsd.edu
Back
to Top |
Location: Call for details
Trial Title and Description: Raloxifene for Women with Alzheimer's
Disease-
The purpose of this study is to determine whether
Raloxifene, a selective estrogen receptor modulator,
improves cognitive function in women with Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: August
2006
Condition: Alzheimer's
disease
Age Eligibility: 60 and
above
Gender Eligibility: Female
Enrollment Goal: 72
Clinical Identifier: NCT00368459
Study Phase: Phase
2
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA)
Contact Information:
Victor
Henderson
650-498-5232
asye@stanford.edu
Sheryl Lynch
317-278-8307
slynch@iupui.edu
Back
to Top |
| COLORADO |
Location: Denver
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Leslie
Moldauer
877-379-3718
Back
to Top |
Location: Denver
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Jack
Klapper
877-379-3718
Back
to Top |
Location: Fort Collins
Rocky
Mountain CC/ Poudre Valley Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Linda M. Hadlow
970-495-7322
Back
to Top |
| CONNECTICUT |
Location: Darien
GSK Clinical
Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Bart
Sloan
877-379-3718
Back
to Top |
Location: Fairfield
GSK Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Monotherapy In Subjects With Mild to
Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD). RSG XR is a
new approach to AD therapy and this study tests a new
way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Not yet
recruiting
Study Dates: Start: January
2007
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 862
Clinical Identifier: NCT00428090
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Kenneth
Siegal
877-379-3718
Back to Top |
Location: New Haven
Yale University
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Amanda Benincasa
203-764-8100
Amanda.Benincasa@yale.edu
For more information, visit www.gapstudy.com
Back to Top
|
Location: New
Haven
GSK Clinical Trials Call Center
Trial Title and Description: Rosiglitazone (Extended Release
Tablets) As Adjunctive Therapy to Acetylcholinesterase
Inhibitors In Mild To Moderate Alzheimer's Disease-
Rosiglitazone (RSG) has been tested in clinical
studies and is approved by the FDA as a treatment for
type II diabetes mellitus, a disease that occurs when
the body is unable to effectively use glucose. RSG XR,
the investigational drug used in this study, is an
extended-release form of RSG. This study tests whether
RSG XR safely provides clinical benefit to people with
mild to moderate Alzheimer’s disease (AD) when
combined with one of the currently approved AD
medications, Aricept®, Razadyne® or Exelon®. RSG XR is
a new approach to AD therapy and this study tests a
new way to treat AD by testing whether one’s genetic
makeup affects the response to the study
drug.
Enrollment Status: Recruiting
Study Dates: Start: July 2006
Condition: Alzheimer's
disease
Age Eligibility: 50-90
Gender Eligibility: Both
Enrollment Goal: 1,392
Clinical Identifier: NCT00348309
Study Phase: Phase
3
Study Type: Interventional
Sponsor: GlaxoSmithKline
Contact Information:
Christopher Van Dyck
877-379-3718
Back
to Top |
Location: Call for details
Trial Title and Description: Evaluation of [123I] AV83 and SPECT
in Patients With Alzheimer's Disease in Comparison to
Healthy Controls-
The underlying goal of this study is to assess
123-I AV83 SPECT imaging as a tool to detect B-amyloid
deposition in the brain of Alzheimer's disease
research participants and age- and gender-matched
healthy subjects.
Enrollment Status: Recruiting
Study Dates: Start: March 2007
Condition: Alzheimer's
disease
Age Eligibility: 50 and
above
Gender Eligibility: Both
Enrollment Goal: 30
Clinical Identifier: NCT00448799
Study Phase: Phase
1
Study Type: Interventional
Sponsor: Institute for
Neurodegenerative Disorders
Molecular
NeuroImaging
Contact Information:
Elizabeth Paul
203-401-4300
epaul@indd.org
Back
to Top |
Location: Call for details
Trial Title and Description: Evaluation of [123I] MNI-187and SPECT
in Patients With Alzheimer's Disease in Comparison to
Healthy Controls-
The underlying goal of this study is to assess
123-I MNI-187 SPECT imaging as a tool to detect
B-amyloid deposition in the brain of Alzheimer's
disease research participants and age- and
gender-matched healthy subjects.
Enrollment Status: Recruiting
Study Dates: Start: April 2007
Condition: Alzheimer's
disease
Age Eligibility: 50 and
above
Gender Eligibility: Both
Enrollment Goal: 30
Clinical Identifier: NCT00456417
Study Phase: Phase
1
Study Type: Interventional
Sponsor: Institute for
Neurodegenerative Disorders
Molecular
NeuroImaging
Contact Information:
Elizabeth Paul
203-401-4300
epaul@indd.org
Back
to Top |
Location: Call for details
Trial Title and Description: Evaluation of [123I] MNI-187and SPECT
in Patients With Alzheimer's Disease in Comparison to
Healthy Controls-
The underlying goal of this study is to assess
123-I MNI-187 SPECT imaging as a tool to detect
B-amyloid deposition in the brain of Alzheimer's
disease research participants and age- and
gender-matched healthy subjects.
Enrollment Status: Recruiting
Study Dates: Start: April 2007
Condition: Alzheimer's
disease
Age Eligibility: 50 and
above
Gender Eligibility: Both
Enrollment Goal: 30
Clinical Identifier: NCT00456417
Study Phase: Phase
1
Study Type: Interventional
Sponsor: Institute for
Neurodegenerative Disorders
Molecular
NeuroImaging
Contact Information:
Elizabeth Paul
203-401-4300
epaul@indd.org
Back
to Top |
| DISTRICT OF COLUMBIA |
Location: Washington, DC
Georgetown University
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Anne Schultz
202-687-8800
ajs235@georgetown.edu
Back to Top |
Location: Washington, DC
Howard University
Trial Title and Description: A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease
The purpose of this study is to determine whether IGIV, 10% treatment, administered at two different doses for 9 and 18 months, results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer’s Disease (AD). Subjects will be randomly assigned to receive intravenous infusions of either of two doses of IGIV, 10% or placebo every two weeks for 70 weeks (36 infusions) as an add-on to conventional Food and Drug Administration (FDA)-approved AD medications.
Enrollment Status: Recruiting
Study Dates: Start: December 2008
Condition: Alzheimer’s disease
Age Eligibility: 50-89
Gender Eligibility: Both
Enrollment Goal: 360
Clinical Identifier: NCT00818662
Study Phase: Phase 3
Study Type: Interventional
Sponsor: Baxter Healthcare Corporation
Contact Information:
Ezenwanyi Ahaghotu
202-865-1972
eahaghotu@howard.edu
Back to Top |
Location: Washington, DC
DC
United MBCCOP
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Dionne
Thorne
202-865-5398
Back
to Top |
Location: Washington ,
DC
George Washington University Medical Center
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Maria-Lourdes Caparas
202-496-6464
Back
to Top |
Location: Washington ,
DC
Silbley Memorial Hospital
Trial Title and Description: Prevention of Alzheimer's Disease by
Vitamin E and Selenium (PREADVISE)-
The Prevention of Alzheimer's disease by Vitamin E
and Selenium (PREADVISE) prevention trial is an
important addition to the Selenium and Vitamin E
Cancer Prevention Trial (SELECT). As a prevention
trial, PREADVISE is trying to find out if taking
Selenium and/or Vitamin E supplements can help to
prevent memory loss and dementia such as Alzheimer's
disease.
Enrollment Status: Recruiting
Study Dates: Start: May 2002
Expected Completion: August 2013
Condition: Alzheimer's
disease
Age Eligibility: 60-90
Gender Eligibility: Male
Enrollment Goal: 10,400
Clinical Identifier: NCT00040378
Study Phase: Phase
3
Study Type: Interventional
Sponsor: National Institute on
Aging (NIA), National Cancer Institute (NCI)
Contact Information:
Sheila Evans
202-243-2320
sevans@sibley.org
Back
to Top |
Location: Call for details
Trial Title and Description: A study of V950 in People with
Alzheimer's Disease-
The purpose of this study is to test the safety,
tolerability and immune response to an investigational
vaccine, V950.
Enrollment Status: Recruiting
Study Dates: Start: April 2007
Condition: Alzheimer's
disease
Age Eligibility: 55 and
above
Gender Eligibility: Both
Enrollment Goal: Call for
details
Clinical Identifier: NCT00464334
Study Phase: Phase
1
Study Type: Interventional
Sponsor: Merck
Contact Information:
Trial
Manager
888-577-8839
Back
to Top |
Location: Call for details
Trial Title and Description: PET Scanning [11C] MeS-IMPY to
Measure Amyloid in Brain-
This study will use positron emission tomography
(PET) to measure a protein called amyloid in the
brains of healthy volunteers and people with
Alzheimer's disease. The tracer used in this study is
a research drug called [11C]
MeS-IMPY.
Enrollment Status: Recruiting
Study Dates: Start: December
2006
Condition: Alzheimer's disease,
Neurodegenerative disease, Dementia
Age
Eligibility: Healthy subjects: 18-80
Alzheimer's diseases: 50-80
Gender
Eligibility: Both
Enrollment
Goal: 15
Clinical
Identifier: NCT00407576
Study
Phase: N/A
Study Type: Observational
Sponsor: National Institute of
Mental Health
Contact Information:
Patient Recruitment and Public Liaison
Office
800-411-1222
Back
to Top |
